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Abstract 
Background: The available diagnostic tools for latent tuberculosis (TB) infection (LTBI) via interferon-gamma (IFN-g) 
release assays (IGRA) are based on ESAT6:CFP10 stimulation. However, the mycobacterial antigen PstS1 is also highly 
immunogenic and some of its fragments, such as PstS1(285–374), have shown higher immunoreactivity in LTBI than in 
active TB. PstS1(285–374), therefore, could increase the accuracy of the existing IGRA to detect LTBI. Thus, a new chi-
meric protein has recently been developed (PstS1(285–374):CFP10) showing potential for LTBI screening of recent close 
contacts (rCt) exposed to Mycobacterium tuberculosis. The aim of this study was to analyze the PstS1(285–374):CFP10 
longitudinal IFN-g profile in comparison to ESAT6:CFP10 and full PstS1/CFP10 stimulation in a rCt cohort and correlate 
the responses to these in-house IGRA with any clinical changes/interventions that might occur.
Methods: A free-of-cost, one-year follow up was offered to 120 rCt recruited in Rio de Janeiro, RJ, Brazil. Whole blood 
short-term (WBA), long-term stimulation (LSA) assays, and the tuberculin skin test (TST) were performed during follow 
up.
Results: Among the enrolled rCt, 44.2% (53/120) returned for re-evaluation and the control group (TST negative, 
n = 17) showed low IFN-g reactivity to all antigen stimulations during the entire follow up, except for one participant 
who had shown radiological evidence of past TB/LTBI. Both incident cases were detected by IGRA-PstS1(285–374):CFP10 
during LTBI and after disease progression. Moreover, subsequent to the prophylactic treatment for LTBI (tLTBI), a sig-
nificant regression in the LSA response was predominantly observed through stimulation of the new chimeric protein 
(8/10, 80%) followed by ESAT6:CFP10 (5/10, 50%) and PstS1/CFP10 (4/10, 40%). No clinical or epidemiological charac-
teristics were exclusively shared among IGRA convertors.
Conclusion: It was demonstrated that the TST negative rCt without radiological evidence of LTBI/TB did not develop 
an IGRA-PstS1(285–374):CFP10 response during the one-year follow up. Moreover, all incident cases were detected by 
our new IGRA; and a significant decrement of LSA-PstS1(285–374):CFP10 reactivity post-prophylactic tLTBI was found. To 
our knowledge, this is the first study to monitor changes in the immune response profile of IGRA-PstS1(285–374):CFP10 
among rCt during a consecutive one-year period, thus providing additional evidence of its potential in the detection 
of LTBI.
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Background
Despite the availability of efficient antibiotic treatments, 
the control of tuberculosis (TB) remains a challenge 
worldwide [1–3]. After an initial Mycobacterium tubercu-
losis (Mtb) infection, approximately 10% will develop TB. 
The great majority (roughly 90%), however, is expected to 
control the bacterial replication and present latent infec-
tion (LTBI) while under the constant risk of developing 
the active form [4].
In active disease, clinical manifestations may help 
diagnose pulmonary TB [5]. In contrast, LTBI is asymp-
tomatic and the lack of adequate diagnostic methods to 
detect latent infection tend to hamper attempts at pre-
venting new incident cases even though the isoniazid 
preventive treatment for LTBI (tLTBI) has been found to 
reduce the risk of developing TB by as much as 90% [2, 
6].
For over a century, LTBI diagnoses have relied on the 
relatively simple, low-cost, tuberculin skin test (TST) [7]. 
However, false-positive results may occur in the TST due, 
in large part, to a previous exposure to environmental 
non-tuberculous mycobacteria [8]. TST also includes the 
boosting phenomenon and the need for a reading visit 
[9]. After development of the commercial interferon-
gamma (IFN-γ) release assay (IGRA), a new tool emerged 
that measures the host T helper 1 (Th1) IFN-γ response 
by priming blood cells with antigens encoded by the Mtb 
region of difference 1 (RD1), the ESAT6, and the CFP10 
[2]. Notwithstanding the evidence afforded by longitudi-
nal studies suggesting that, among high-risk populations, 
TST is more sensitive [10] and cost-effective [2], there is 
a global tendency, especially in high-income countries, 
to replace TST by a single-step commercial IGRA-RD1 
or simply apply it after a prior TST screening [11]. But, 
these approaches would necessarily increase the financial 
burden of global TB control programs, primarily in low- 
and middle-income countries [1, 12]. Hence, the need for 
new, more cost-effective, and reliable tools/antigens that 
could safely substitute or add sensitivity to the LTBI bio-
markers currently in use continues to exist.
A new PstS1(285–374):CFP10 fusion protein has recently 
been designed by our group. Among LTBI, in compari-
son to the traditional ESAT6:CFP10, our new chimeric 
protein has demonstrated similar immunoreactiv-
ity while slightly increasing the detection of TST posi-
tive (TSTpos) rCt by both WBA and LSA [13]. This 
new protein was also able to identify an incident case 
that progressed from LTBI to active pulmonary TB 
within a short period in the absence of a response to 
LSA-ESAT6:CFP10 [13]. As both TST and IGRA RD1-
based have their limitations, continued surveillance of 
host immunomodulatory changes for a specific length 
of time, and especially after recent Mtb exposure, may 
result in revealing new antigens that could potentially be 
used to either compose new diagnostic tests or augment 
the effectiveness of current ones. In this connection, the 
aim of the present study was to determine the longitudi-
nal IFN-γ profile via whole blood short-term (WBA) and 
peripheral blood mononuclear cell (PBMC) long-term 
stimulation (LSA) assays in a cohort of recent close con-
tacts (rCt) exposed to a pulmonary TB index case (IC). 
All participants were recruited from the general patient 
population seeking treatment at the public health care 
facilities located in the City of Rio de Janeiro. The pre-
sent study correlated the modulations detected in WBA 
and LSA responses under PstS1(285–374):CFP10, PstS1/
CFP10, and ESAT6:CFP10 stimuli resulting from clinical 
changes and antibiotic interventions.
Methods
Study samples
The present investigation was carried out on samples 
previously collected by the TB Control Program at the 
Clementino Fraga Filho University Hospital in Rio de 
Janeiro, RJ, Brazil [13]. All rCt recruited between March 
2010 and August 2012 were >17 years of age and tested 
negatively for the human immunodeficiency virus (HIV). 
Upon obtaining informed oral and written consent, 
blood samples were collected prior to administering the 
Mantoux TST [13].
According to Brazilian Ministry of Health recom-
mendations [14], all close contacts showing a TSTpos 
(cut-off ≥5 mm) with no indication of disease were con-
sidered LTBI or as having pulmonary TB in light of their 
respective microbiological, radiological, and clinical find-
ings and were subsequently offered specific free-of-cost 
treatment.
Prospective analysis
The TB Control Program offered clinical follow up to all 
rCt and the TST negative cases were retested at four-
month intervals and after the twelfth month, while TST 
positive subjects were just treated and clinically followed. 
In a previous study [13] by our group analyzing the poten-
tial use of PstS1 (285–374):CFP10 as a new LTBI biomarker, 
blood samples were taken upon enrollment (T0). In the 
present study, the rCt were followed up longitudinally 
for a year (T1), except for the TST convertors and inci-
dent cases, from whom blood was collected upon a skin 
test conversion or TB diagnosis. For the in  vivo TST, a 
conversion was classified as an augmentation of ≥10 mm 
in comparison to a previously reported test. Conversely, 
for the in  vitro WBA and LSA, a conversion/regression 
response was defined as a respective augmentation or 
decrement that crosses the cut-off points in the follow-up 
tests in comparison to baseline reactivity.
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Mycobacterium tuberculosis antigens
The Mtb recombinant antigens ESAT6:CFP10 and PstS1/
CFP10 were kindly provided by Dr. Tom Ottenhoff (Lei-
den University Medical Centre, The Netherlands) and Dr. 
Mahavir Sigh (Helmholtz Centre for Infection Research, 
Germany), respectively. The chimeric protein PstS1(285–374): 
CFP10 was produced in our laboratory, as previously 
described [13]. In brief, sequences of the selected genes 
were amplified from M. tuberculosis H37Rv genomic DNA 
using gene-specific primers. Each fragment was then 
cloned, fused, and transformed for recombinant expres-
sion in Escherichia coli.
Whole blood (WBA) and peripheral blood mononuclear cell 
(PBMC) long‑term stimulation assays (LSA)
As previously described [13], heparinized venous blood 
was collected and separated for WBA (1 mL per well for 
22  h) or for PBMC isolation followed by LSA (1 ×  105 
cells/well, 5  days) in the presence or absence of Conca-
navalin-A/antigens. The culture supernatants were col-
lected and stored at −20 °C until tested.
The commercial ELISA Duo-Set-IFN-γ kit (R&D, USA) 
was used to evaluate IFN-γ secretion following the manu-
facturer’s recommendations. After subtraction of the appro-
priate unstimulated control, the results were expressed in 
picograms/milliliters (pg/mL). All cut-off points were pre-
viously standardized (WBA: ESAT6:CFP10  =  10  pg/mL; 
PstS1/CFP10 = 10.5 pg/mL; PstS1(285–374):CFP10 = 29.5 pg/
mL; LSA: 100 pg/mL each) [13].
Data analysis
Prism5 (GraphPad Software, USA) and SPSS 17.0 (IBM, 
USA) were used to generate plots and for statistical 
analyses. The Mann–Whitney and Kruskal–Wallis non-
parametric tests were utilized to analyze significant 
differences between 2 or  >2 groups, respectively. The 
Wilcoxon Signed Rank Test was adopted for longitudinal 
analyses. P values of <0.05 were considered significant.
Results
Study participants
According to Brazilian Ministry of Health guidelines, 
a clinical evaluation/follow up and TB prophylaxis are 
not mandatory after reported exposure to Mtb. Of all 
enrolled rCt, 44.2% (53/120) returned for the 1-year re-
evaluation. They were then organized into study groups 
according to their baseline TST and clinical outcomes, 
as follows: Group I, TST negative (TSTneg: WBA, n = 10; 
LSA, n =  17); Group II, TST conversion (WBA, n =  2; 
LSA, n  =  4); Group III, TSTpos submitted to tLTBI 
(WBA, n = 17; LSA, n = 25); Group IV, TSTpos untreated 
(WBA, n =  4; LSA, n =  5); and Group V: TB incident 
cases (WBA, n = 2; LSA, n = 2) (Fig. 1).
As shown in Table  1, while nearly half (49.1%) of the 
enrolled rCt inhabited the same dwelling as their IC, 
the proportions of gender and BCG vaccination status 
were slightly asymmetrical (58.5% was female and 62.3% 
had a BCG vaccination scar). The mean ages were simi-
lar among all groups, varying between 43.5 (±14.4) and 
46.4 (±18.5) years of age (p ≥ 0.051), except for Group 
V (61.5 ± 3.5 years, p = 0.023). As expected, there was a 
statistical difference (p ≤  0.016) when comparing mean 
skin test induration between TSTpos (Group III or IV) 
and TSTneg (Group I or II) rCt.
IGRA reactivity
Due to ethical limitations, the adequate amount of blood 
for both assays was unavailable for some rCt, thus justify-
ing the discrepancies between the sample sizes of WBA 
and LSA.
With the exception of one outlier at T1 (Black cirle, 
Fig. 2a) who had a TB compatible chest x-ray since 1978 
with no other clinical manifestations, the mean amount 
of IFN-γ detected in Group I was similarly low at the two 
time-points for both IGRAs (p ≥ 0.109). In contrast, the 
PBMCs of participants with a TST conversion (Group II, 
Fig. 2b) or untreated TSTpos (Group IV, Fig. 2d) demon-
strated a slight-to-moderate increase in their mean IGRA 
responses (p ≥ 0.109).
An exclusive, antagonic IFN-γ modulation during 
short-and long-term incubation periods was noticed 
in Groups III (tLTBI) and V (TB). While the mean LSA 
response dropped post-tLTBI (Fig.  2c, p  ≥  0.071), the 
WBA response increased (p ≥  0.084). Interestingly, the 
Group V response was the opposite: the mean WBA 
response dropped and LSA increased along the follow-
up period, principally in relation to ESAT6:CFP10 and 
PstS1(285–374):CFP10 (Fig. 2e, p ≥ 0.18).
Despite the tendencies regarding IFN-γ modulation, 
no statistically significant changes were identified when 
comparing paired IFN-γ mean ± standard deviation (SD) 
reactivity to any antigenic stimulation (Fig. 2, p ≥ 0.071). 
The same was observed for concanavalin A (p ≥ 0.087) in 
both the WBA (mean ± SD, pg/mL, T0 = 74.1 ± 99.0 and 
T1 = 84.2 ± 97.6; n = 35) and LSA (mean ± SD, pg/mL: 
T0 = 2268.9 ± 1831.1 and T1 = 1704.9 ± 874.8; n = 55). 
All the mean IFN-γ responses are shown in Additional 
file 1: Table S1.
Interferon-gamma response regressions or conversions 
were observed in some rCt. Either WBA or LSA con-
versions occurred in all individuals regardless of group 
(WBA-convertors: Group I: 5/14 [35.7%]; Group II: 1/14 
[7.1%]; Group III: 7/14 [50%]; Group IV: 1/14 [7.1%]. 
LSA-convertors: Group I: 3/13 [23.1%]; Group II: 2/13 
[15.4%]; Group III: 5/13 [38.5%]; Group IV: 2/13 [15.4%]; 
and Group V: 1/13 [7.6%]) as well as to all antigens (Fig. 3 
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a, b). However, no clinical or epidemiological characteris-
tics were exclusively shared among the IGRA convertors.
Conversely, regression from a previously positive IFN-γ 
response was mostly seen in Group III whatever the 
stimulus (Group III regressors/Total regressors: WBA: 
6/9, 66.7%; LSA: 10/12, 83.3%), but principally to the new 
PstS1(285–374):CFP10 antigen (WBA: ESAT6:CFP10: 2/9, 
22.2%; PstS1/CFP10: 7/9, 77.8%; PstS1(285–374):CFP10: 8/9, 
88.9%. LSA: PstS1/CFP10: 4/12, 33.3%; ESAT6:CFP10: 
7/12, 58.3%; PstS1(285–374):CFP10: 8/12, 66.6%) (Fig. 3 c, d).
Effects of tLTBI on in‑house IGRA responses
Despite the presence of a TST positive reaction, some 
of the rCt submitted to tLTBI lacked baseline IGRA 
reactivity. We, thus, opted for the stratification of Group 
III individuals according to their baseline IFN-γ response 
(responders/non-responders) to each stimulus (Fig.  4). 
No statistical significant changes were observed in the 
sub-cohort of non-responder rCt. On the other hand, 
there was a statistically significant decrease among the 
LSA-responders to ESAT6:CFP10 (from 758.5 ±  731 to 
231.2 ± 240.1 pg/mL, p = 0.027) as well as to PstS1(285-374): 
CFP10 (from 588.6  ±  650.0 to 106.7  ±  288.4  pg/mL, 
p =  0.004), albeit with a borderline significance relative 
to the full PstS1/CFP10 combination (from 469.2 ± 306.8 
and 28.0  ±  45.7  pg/mL, p  =  0.06). One rCt preven-
tively treated with isoniazid did not show any significant 
changes in IGRA response modulation over time (Fig. 4, 
Fig. 1 Baseline of study groups (T0) and follow-up (T1) characteristics. Recent close contact (rCt) screening via tuberculin skin test (TST), at T0, and 
clinical outcomes after 1-year follow up (T1) resulting in five different groups. All rCt-TST
pos (≥5 mm) were offered free-of-cost treatment for latent 
tuberculosis infection (tLBTI). A blood specimen was collected upon TST conversion or an active TB diagnosis
Table 1 Baseline demographic characteristics of the study populationa
Group I TSTneg, Group II TST convertors, Group III TSTpos submitted to treatment for latent tuberculosis infection (tLTBI), Group IV TSTpos not submitted to the tLTBI, and 
Group V developed active pulmonary TB. Mann–Whitney test was used to generate p values
a BCG Bacille Calmette Guérin, mm millimeters, TST tuberculin skin test, SD standard deviation
The symbols * and ¥ were used to identify p values <0.05 comparing to Group I or II, respectively













BCG scar 33 (62.3) 9 (52.9) 4 (100) 18 (72) 2 (40) 0 (0)
Females 31 (58.5) 8 (47.1) 3 (75) 16 (64) 3 (60) 1 (50)
Household contact 26 (49.1) 5 (29) 2 (50) 10 (40) 2 (40) 2 (100)
Mean (±SD) age, years 45.1 (±13.2) 43.9 (±13.0) 43.5 (±14.4) 44.5 (±12.6) 46.4 (±18.5) 61.5 (±3.5)¥
Mean (±SD) TST induration, mm 7.2 (±6.1) 0.4 (±1.2) 1.8 (±2.1) 11.8 (±3.7)*¥ 9.8 (± 3.6)*¥ 12.5 (±3.5)*
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White square). Of note, his/her respective IC was later 
diagnosed with MDR-Mycobacterium tuberculosis (mul-
tidrug resistant to isoniazid and rifampicin) infection.
Discussion
Diagnostic tests to accurately detect an invasive microbe 
play key roles in patient management and the control of 
infectious diseases [15]. A previous exploratory investi-
gation conducted by our group showed that, among TB 
cases, the combination of full PstS1 with CFP10 induced 
IFN-γ response levels similarly to what occurred follow-
ing ESAT6:CFP10 stimulation [16]. In another study, 
differential immune responses to PstS1 peptides were 
observed [17]. It was also found that the peptide included 
in our PstS1(285–374):CFP10 fusion protein induced higher 
T cell proliferative responses in LTBI compared to pul-
monary TB donors [17]. Additionally, despite the very 
low-level expression of the PstS1 protein by M. bovis 
BCG [18], the high immunogenicity of this protein dur-
ing TB has been proven in a variety of studies [16, 17, 
19–22]. In fact, we have likewise reported [13] a simi-
larly high specificity, for LTBI detection, in PstS1(285–374): 
CFP10 and ESAT6:CFP10 IFN-γ responses (∼90% speci-
ficity) [13], including those to the full PstS1/CFP10 (per-
sonal communication). Nevertheless, among TSTpos 
contacts, the chimeric protein had the highest detection 
rate (WBA: 23/54, 42.6%; LSA: 26/54, 48.2%), followed 
by ESAT6:CFP10 (WBA: 18/54, 33.3%; LSA: 24/54, 
44.4%) [13], and PstS1/CFP10 (WBA: 20/54, 33.3%; 
LSA: 22/54, 40.7%, personal communication). Since the 
new immunogenic fusion protein PstS1(285–374):CFP10 
seems to be more suitable for adding sensitivity to 
ESAT6:CFP10 than the full PstS1/CPF10 combination, it 
was decided to investigate further. Indeed, there is much 
evidence suggesting that IGRA-ESAT6:CFP10 will be 
false-negative in a significant proportion of both latent 
and actively-infected Mtb individuals [23]. However, in 
the absence of a gold-standard test for LTBI, questions 
arose concerning the practical significance of detecting 
TSTpos/ESAT6:CFP0neg/PstS1(285–374):CFP10pos individu-
als. Thus, longitudinal studies with individuals recently 
exposed to Mtb should help to clarify any remaining 
doubts concerning the absolute reliability of the newly-
proposed LTBI diagnostic method.
The mechanisms involved in the progression from 
LTBI to TB are not yet fully understood. The develop-
ment of TB is associated with a failure in the immune 
surveillance system of the host with a Th2 polarization 
that inhibits the host protective Th1 response (IFN-
γ, interleukin-12, and tumor necrosis factor [24–27]. 
The incident cases presented a coincident decrement of 
WBAs, probably due to an inefficient activation of effec-
tor Th1 cell repertories [26]. As seen in Fig. 2e, however, 
by LSA, memory and resting T cells with a longer incuba-
tion period were able to differentiate and initiate IFN-γ 
production [28–30]. Other studies have shown similar 
IFN-γ responses in such assays [30–33]. In the end, these 
occurrences might reveal that some of the host cell popu-
lations would still be able to mount a Th1-IFN-γ response 
to Mtb antigens even after the development of TB. It is 
Fig. 2 Mean, standard deviation (SD) of interferon-gamma responses at enrollment (T0) and after follow up (T1). Longitudinal analysis via Wilcoxon 
signed rank test of mean interferon-gamma levels after short- (WBA) and/or long-term (LSA) stimulation assays priming blood cells from recent 
close contacts with mycobacterial antigens [ESAT6:CFP10, PstS1/CFP10, and PstS1(285–374):CFP10] upon enrollment (T0) and after one-year follow 
up (T1). In some special cases, a blood specimen was collected upon TST conversion or an active TB diagnosis. All individuals in the study were strati-
fied according to their initial (T0) tuberculin skin test (TST) response and T1 outcome, as follows: a Group I TST
neg (n, WBA = 10, LSA = 17); b Group II 
TST convertors (n, WBA = 2, LSA = 4); c Group III TSTpos treated for latent tuberculosis infection (tLTBI) (n, WBA = 17, LSA = 25); d Group IV TSTpos not 
treated for tLTBI (n, WBA = 4, LSA = 5); and e Group V TB incident cases (n = 2). Short bars standard deviation
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noteworthy that the small sample size may have limited 
our ability to detect a significant modulation. As such, it 
is clear that additional studies are required to validate or 
not the reported dichotomic IGRA modulation during 
TB progression.
Individuals from different groups not sharing any inde-
pendent, mutually exclusive clinical or epidemiological 
risk factors demonstrated an IGRA conversion. To elu-
cidate these cases, it must be taken into account that: 
(1) An IGRA response may be affected by a prior TST 
since the test consists of the intradermal inoculation 
of a Mtb crude antigenic pool [34]; (2) in a high-trans-
mission setting such as Rio de Janeiro, re-exposure to 
Mtb often leads to the maintenance or incensement of 
the IFN-γ responses [35, 36]; and (3) the lack of a base-
line (T0) response may be due to the “window period” 
between exposure to a pathogen and development of an 
adaptive response. A dynamic characteristic of the IGRA 
response over time has been previously described [37], 
Thus, the idea that minor non-specific differences in the 
IFN-γ response should also be expected. Nonetheless, 
the reversion to negativity predominantly seen in Group 
Fig. 3 Venn diagrams for the follow up of in-house interferon gamma release assay results. Distribution of interferon-gamma response conversion 
(a, b) or regression (c, d) at follow-up whole-blood (WBA) and long-term (LSA) stimulation assays. Recent close contact’s blood specimens were 
primed with Mycobacterium tuberculosis antigens (ESAT6:CFP10, PstS1/CFP10, and PstS1(285–374):CFP10). Each symbol represents one rCt from the 
respective follow-up group (Black square Group I TSTneg; Black diamond Group II TST convertors; Double dagger Group III TSTpos treated for latent tuber-
culosis infection (tLTBI); White triangle Group IV TSTpos not tLTBI; Black circle Group V TB incident cases)
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III (Fig. 3) corroborates previous findings regarding LTBI 
[34, 35, 38–40] and TB [41, 42] individuals receiving anti-
biotic therapy. Of note is the recent contact of a MDR-
TB index case who did not demonstrate a LSA regression 
post-tLTBI with isoniazid, suggesting that antibiot-
ics were ineffective in this case (Fig.  4, White square). 
It, therefore, could be surmised that the new LSA 
PstS1(285–374):CFP10-based might prove useful in moni-
toring changes in the immune response after completion 
of preventive therapy.
In the present study, both WBA and LSA displayed a 
few discordant results. Similar data have been gathered 
via commercial kits [13, 43]. This result was not surpris-
ing since the responses of different immune cell subsets 
are elicited in short- and long-term cultures [28, 29]. 
From an operational standpoint, WBA is faster, more 
cost-effective, and easier. Contrariwise, a significant 
post-tLTBI regression response during the follow-up 
period only occurred in LSA (Fig.  3). Therefore, in set-
tings in which higher sensitivity is required, an approach 
that could be considered would be combining both test 
results to characterize LTBI [28] since WBA and LSA 
have particularities that must be reckoned with before 
application. It should be emphasized that all TB inci-
dent cases were detected by WBA-PstS1(285–374):CFP10, 
LSA-PstS1(285–374):CFP10, and TST, but that the IGRA 
tests showed better selectivity among the 108 rCt (WBA-
PstS1(285–374):CFP10: 28/108, 25.9%; LSA-PstS1(285–374): 
CFP10: 31/108, 28.7%; TST: 54/108, 50%) [13]. More-
over, the IGRA PstS1(285-374):CFP10-based showed 
moderate-to-substantial kappa (κ) agreement under 
ESAT6:CFP10 stimulation in WBA and LSA (κ = 0.50–
0.71), respectively [13]. If these findings are corroborated 
in further investigations, the use of any of the newly-pro-
posed IGRAs instead of TST may be able to reduce the 
number of unnecessary tLTBI prescriptions.
Conclusion
This is the first study to monitor changes in the immune 
response profile of the IGRA PstS1(285–374):CFP10-based 
among rCt during a 12-month period. As a result, addi-
tional information has been acquired about this new 
LTBI biomarker in an effort to highlight its poten-
tial. Without a doubt, the sample size and prophylac-
tic tLTBI are limitations, which may contribute to an 
underestimation of the negative/positive predictive 
values of the test to detect TB progression. However, 
it is our belief that the participants in our study groups 
accurately reflect the public at large in routine clini-
cal practice in a scenario with a high TB-burden and 
BCG vaccination coverage, in which prior Mtb expo-
sure or re-exposure after initiating tLTBI cannot be 
ruled out even with respect to TSTneg/ESAT6:CFP10neg 
Fig. 4 Longitudinal interferon-gamma responses post-prophylactic 
treatment for latent tuberculosis infection. Longitudinal analysis upon 
enrollment (T0) and after 1-year follow up (T1) of mean interferon-
gamma levels via short- (WBA) and long-term (LSA) stimulation 
assays with blood specimens from recent close contacts of TSTpos 
treated for latent tuberculosis infection (Black circle) and stratified 
according to their baseline interferon-gamma response (non-
responders and responders) to each Mycobacterium tuberculosis 
antigen: a ESAT6:CFP10; b PstS1/CFP10; and c PstS1(285–374):CFP10. 
*p < 0.05 via Wilcoxon signed rank test. White square recent close 
contact exposed to a multidrug-resistant Mycobacterium tuberculosis 
strain
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individuals [2]. Interestingly, except for one outlier with 
radiological evidence of long-term LTBI, Group I par-
ticipants (TSTneg, n = 17) continued having a very low 
IFN-γ response to PstS1(285–374):CFP10-based WBA 
and LSA during the entire follow up (Additional file 1: 
Table S1). LSA regression was predominantly observed 
among rCt submitted to tLTBI (Group III, PstS1(285–374): 
CFP10 [n  =  09], p  <  0.05, Figs.  3 and 4). In addition, 
both incident cases were detected early by IGRA-
PstS1(285–374):CFP10 before showing microbiological 
evidence of active pulmonary TB. Together, these data 
provide more positive evidence about the potential of 
IGRA PstS1(285–374):CFP10-based for LTBI diagnoses. It 
is of utmost importance that low- and middle-income 
countries invest in the development of accurate, reli-
able, and cost-effective LTBI diagnostic tools to ensure 
the proper maintenance of their TB control programs. 
In light of the previous [13] and present evidence, we 
are encouraged to proceed to a next-step: validation of 
the use of IGRA-PstS1(285–374):CFP10 in cohorts from 
different geographical areas worldwide.
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